Erwan Bezard
Erwan Bezard
Verified email at u-bordeaux.fr - Homepage
Title
Cited by
Cited by
Year
Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms
MC Rodriguez-Oroz, M Jahanshahi, P Krack, I Litvan, R Macias, E Bezard, ...
The Lancet Neurology 8 (12), 1128-1139, 2009
7122009
Pathophysiology of levodopa-induced dyskinesia: potential for new therapies
E Bezard, JM Brotchie, CE Gross
Nature Reviews Neuroscience 2 (8), 577-588, 2001
5522001
Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaque …
E Bezard, S Dovero, C Prunier, P Ravenscroft, S Chalon, D Guilloteau, ...
Journal of Neuroscience 21 (17), 6853-6861, 2001
5102001
Lewy body extracts from Parkinson disease brains trigger α‐synuclein pathology and neurodegeneration in mice and monkeys
A Recasens, B Dehay, J Bové, I Carballo‐Carbajal, S Dovero, ...
Annals of neurology 75 (3), 351-362, 2014
4152014
Priorities in Parkinson's disease research
WG Meissner, M Frasier, T Gasser, CG Goetz, A Lozano, P Piccini, ...
Nature reviews Drug discovery 10 (5), 377-393, 2011
4112011
Attenuation of levodopa-induced dyskinesia by normalizing dopamine D 3 receptor function
E Bézard, S Ferry, U Mach, H Stark, L Leriche, T Boraud, C Gross, ...
Nature medicine 9 (6), 762-767, 2003
4032003
Increased D1 dopamine receptor signaling in levodopa‐induced dyskinesia
I Aubert, C Guigoni, K Håkansson, Q Li, S Dovero, N Barthe, BH Bioulac, ...
Annals of Neurology: Official Journal of the American Neurological …, 2005
3902005
Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders
V Voon, PO Fernagut, J Wickens, C Baunez, M Rodriguez, N Pavon, ...
The Lancet Neurology 8 (12), 1140-1149, 2009
3482009
Novel pharmacological targets for the treatment of Parkinson's disease
AHV Schapira, E Bezard, J Brotchie, F Calon, GL Collingridge, B Ferger, ...
Nature reviews Drug discovery 5 (10), 845-854, 2006
3362006
Presymptomatic compensation in Parkinson's disease is not dopamine-mediated
E Bezard, CE Gross, JM Brotchie
Trends in neurosciences 26 (4), 215-221, 2003
3352003
The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders
P Sokoloff, J Diaz, BL Foll, O Guillin, L Leriche, E Bezard, C Gross
CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS …, 2006
3312006
Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives
AHV Schapira, CW Olanow, JT Greenamyre, E Bezard
The Lancet 384 (9942), 545-555, 2014
3252014
A brain–spine interface alleviating gait deficits after spinal cord injury in primates
M Capogrosso, T Milekovic, D Borton, F Wagner, EM Moraud, ...
Nature 539 (7628), 284-288, 2016
3032016
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
MF Bastide, WG Meissner, B Picconi, S Fasano, PO Fernagut, M Feyder, ...
Progress in neurobiology 132, 96-168, 2015
2662015
Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations
B Dehay, M Bourdenx, P Gorry, S Przedborski, M Vila, S Hunot, ...
The Lancet Neurology 14 (8), 855-866, 2015
2642015
Electrophysiological and metabolic evidence that high‐frequency stimulation of the subthalamic nucleus bridles neuronal activity in the subthalamic nucleus and the substantia …
C Tai, T Boraud, E Bezard, B Bioulac, C Gross, A Benazzouz
The FASEB journal 17 (13), 1820-1830, 2003
2632003
Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter
E Bezard, CE Gross, MC Fournier, S Dovero, B Bloch, M Jaber
Experimental neurology 155 (2), 268-273, 1999
2501999
High frequency stimulation of the internal Globus Pallidus (GPi) simultaneously improves parkinsonian symptoms and reduces the firing frequency of GPi neurons in the MPTP …
T Boraud, E Bezard, B Bioulac, C Gross
Neuroscience letters 215 (1), 17-20, 1996
2451996
Lysosomal impairment in Parkinson's disease
B Dehay, M Martinez‐Vicente, GA Caldwell, KA Caldwell, Z Yue, ...
Movement Disorders 28 (6), 725-732, 2013
2402013
Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration
B Dehay, A Ramirez, M Martinez-Vicente, C Perier, MH Canron, ...
Proceedings of the National Academy of Sciences 109 (24), 9611-9616, 2012
2362012
The system can't perform the operation now. Try again later.
Articles 1–20